Boston Scientific Co. (NYSE:BSX) Shares Sold by Outfitter Financial LLC

Outfitter Financial LLC lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,757 shares of the medical equipment provider’s stock after selling 425 shares during the period. Boston Scientific comprises about 2.0% of Outfitter Financial LLC’s holdings, making the stock its 17th largest position. Outfitter Financial LLC’s holdings in Boston Scientific were worth $2,479,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Stanley Laman Group Ltd. purchased a new stake in Boston Scientific in the 3rd quarter valued at $210,000. Private Advisor Group LLC raised its holdings in shares of Boston Scientific by 2.7% in the third quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after buying an additional 944 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its holdings in shares of Boston Scientific by 37.5% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 11,657 shares of the medical equipment provider’s stock valued at $977,000 after buying an additional 3,177 shares during the last quarter. McAdam LLC purchased a new position in shares of Boston Scientific during the third quarter worth about $295,000. Finally, Axecap Investments LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $3,000,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.41 on Friday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $155.57 billion, a P/E ratio of 84.33, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The firm has a 50-day moving average price of $97.69 and a two-hundred day moving average price of $89.06. Boston Scientific Co. has a twelve month low of $65.33 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Wells Fargo & Company increased their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Friday, January 10th. Royal Bank of Canada boosted their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Raymond James raised their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Finally, UBS Group lifted their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.39.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. The trade was a 22.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 153,640 shares of company stock valued at $15,718,289 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.